Payment overview · 2025
General Payments
$4,606.66
196 reported records · 31 companies
Healthcare provider profile · identity verified
George Hall, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1639171143
Verified facts
What the public records show
CMS Open Payments records show George Hall, MD received $4,606.66 in general payments during 2025 across 196 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Edarbi, Eliquis, Farxiga, Gemtesa, Jardiance, Nexletol, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 288 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 493 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Edarbi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $593.44 | 12.9% | 29 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $513.65 | 11.2% | 25 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $362.97 | 7.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $336.96 | 7.3% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $278.25 | 6.0% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $265.03 | 5.8% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $254.40 | 5.5% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $243.51 | 5.3% | 11 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $225.97 | 4.9% | 8 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $184.14 | 4.0% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $168.74 | 3.7% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $164.86 | 3.6% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.91 | 3.2% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $121.66 | 2.6% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $100.00 | 2.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.93 | 1.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.50 | 1.4% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.26 | 1.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.97 | 1.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.88 | 1.0% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.76 | 1.0% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $45.53 | 1.0% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.42 | 0.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $34.27 | 0.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.94 | 0.7% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $32.81 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.05 | 0.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.13 | 0.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.00 | 0.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.44 | 0.5% | 1 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.28 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,561.66 | 195 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $497.91 | 27 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $422.51 | 21 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $362.97 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $335.19 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $228.34 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $220.71 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $216.69 | 12 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $184.14 | 10 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $168.74 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $164.86 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $148.41 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $121.66 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $108.04 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $86.25 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $75.00 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.71 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $65.41 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.50 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.50 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $52.26 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.97 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.88 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $46.76 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $45.53 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.68 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.68 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $39.42 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $32.81 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $30.05 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $25.73 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 36 | exact normalized | Medicare Part D |
| EDARBI edarbi |
2025 | Edarbi | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 493 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 239 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 92 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 356 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 183 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
36 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
89 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
288 | 83 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
56 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
493 | 167 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
239 | 79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 42 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
44 | 18 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
114 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
356 | 182 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
183 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
239 | 79 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
92 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2603 | 986 |
| Donepezil Hcl | Donepezil Hcl | 2013 | 743 |
| Vascepa | Icosapent Ethyl | 1730 | 514 |
| Amlodipine Besylate | Amlodipine Besylate | 1474 | 512 |
| Diclofenac Epolamine | Diclofenac Epolamine | 1424 | 369 |
| Losartan Potassium | Losartan Potassium | 1396 | 499 |
| Montelukast Sodium | Montelukast Sodium | 1101 | 399 |
| Meclizine Hcl | Meclizine Hcl | 1065 | 432 |
| Metformin Hcl | Metformin Hcl | 986 | 334 |
| Omeprazole | Omeprazole | 928 | 328 |
| Alendronate Sodium | Alendronate Sodium | 756 | 266 |
| Simvastatin | Simvastatin | 719 | 249 |
| Tamsulosin Hcl | Tamsulosin Hcl | 683 | 269 |
| Meloxicam | Meloxicam | 675 | 393 |
| Fluticasone Propionate | Fluticasone Propionate | 666 | 285 |
| Diclofenac Sodium | Diclofenac Sodium | 662 | 309 |
| Celecoxib | Celecoxib | 569 | 304 |
| Ammonium Lactate | Ammonium Lactate | 521 | 223 |
| Metoprolol Succinate | Metoprolol Succinate | 517 | 189 |
| Ezetimibe | Ezetimibe | 495 | 178 |
| Farxiga | Dapagliflozin Propanediol | 493 | 167 |
| Raloxifene Hcl | Raloxifene Hcl | 490 | 172 |
| Finasteride | Finasteride | 471 | 189 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 461 | 154 |
| Azithromycin | Azithromycin | 446 | 364 |
| Trazodone Hcl | Trazodone Hcl | 441 | 151 |
| Gabapentin | Gabapentin | 423 | 157 |
| Pioglitazone Hcl | Pioglitazone Hcl | 397 | 122 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 395 | 172 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 394 | 138 |
| Azelastine Hcl | Azelastine Hcl | 393 | 161 |
| Colesevelam Hcl | Colesevelam Hcl | 390 | 124 |
| Famotidine | Famotidine | 390 | 176 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 384 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 358 | 129 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 356 | 182 |
| Fluoxetine Hcl | Fluoxetine Hcl | 318 | 124 |
| Clopidogrel | Clopidogrel Bisulfate | 315 | 119 |
| Memantine Hcl Er | Memantine Hcl | 290 | 88 |
| Synthroid | Levothyroxine Sodium | 288 | 83 |
| Atenolol | Atenolol | 277 | 88 |
| Lisinopril | Lisinopril | 260 | 114 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 243 | 142 |
| Jardiance | Empagliflozin | 239 | 79 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 239 | 65 |
| Januvia | Sitagliptin Phosphate | 237 | 73 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 236 | 73 |
| Loperamide | Loperamide Hcl | 228 | 148 |
| Folic Acid | Folic Acid | 211 | 89 |
| Allopurinol | Allopurinol | 210 | 73 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 208 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 197 | 98 |
| Amoxicillin | Amoxicillin | 194 | 158 |
| Mupirocin | Mupirocin | 190 | 129 |
| Fluocinonide | Fluocinonide | 188 | 125 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 63 |
| Halobetasol Propionate | Halobetasol Propionate | 185 | 123 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 183 | 55 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 173 | 172 |
| Carvedilol | Carvedilol | 167 | 50 |
| Glipizide Er | Glipizide | 167 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 53 |
| Mometasone Furoate | Mometasone Furoate | 162 | 76 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 155 | 50 |
| Fenofibrate | Fenofibrate,micronized | 148 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 51 |
| Acarbose | Acarbose | 138 | 43 |
| Clobetasol Propionate | Clobetasol Propionate | 138 | 71 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 136 | 86 |
| Xarelto | Rivaroxaban | 136 | 39 |
| Pregabalin | Pregabalin | 134 | 50 |
| Dutasteride | Dutasteride | 132 | 44 |
| Icosapent Ethyl | Icosapent Ethyl | 132 | 79 |
| Naproxen | Naproxen | 130 | 91 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 130 | 38 |
| Enalapril Maleate | Enalapril Maleate | 129 | 39 |
| Eliquis | Apixaban | 127 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 127 | 53 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 126 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 35 |
| Lidocaine | Lidocaine | 121 | 34 |
| Dexlansoprazole Dr | Dexlansoprazole | 119 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 118 | 29 |
| Repatha Sureclick | Evolocumab | 118 | 26 |
| Vemlidy | Tenofovir Alafenamide | 114 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 112 | 37 |
| Tradjenta | Linagliptin | 112 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 111 | 100 |
| Ketoconazole | Ketoconazole | 111 | 35 |
| Olanzapine | Olanzapine | 107 | 28 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 106 | 102 |
| Hydrocortisone | Hydrocortisone | 106 | 70 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 87 |
| Metoclopramide Hcl | Metoclopramide Hcl | 102 | 63 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 101 | 36 |
| Procto-Med Hc | Hydrocortisone | 101 | 54 |
| Myrbetriq | Mirabegron | 99 | 27 |
| Glimepiride | Glimepiride | 94 | 28 |
| Rybelsus | Semaglutide | 92 | 26 |
| Nexium | Esomeprazole Magnesium | 90 | 22 |
| Promethazine Hcl | Promethazine Hcl | 90 | 59 |
| Linzess | Linaclotide | 89 | 27 |
| Nifedipine Er | Nifedipine | 86 | 30 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 83 | 60 |
| Telmisartan | Telmisartan | 77 | 22 |
| Memantine Hcl | Memantine Hcl | 69 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 26 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 69 | 21 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 65 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 19 |
| Propranolol Hcl | Propranolol Hcl | 63 | 24 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 62 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 59 | 35 |
| Ibuprofen | Ibuprofen | 58 | 43 |
| Potassium Chloride | Potassium Chloride | 58 | 33 |
| Silodosin | Silodosin | 58 | 18 |
| Prolia | Denosumab | 56 | 46 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 22 |
| Fenofibrate | Fenofibrate | 54 | 19 |
| Livalo | Pitavastatin Calcium | 53 | 19 |
| Metformin Hcl Er | Metformin Hcl | 53 | 22 |
| Bepotastine Besilate | Bepotastine Besilate | 52 | 21 |
| Spironolactone | Spironolactone | 52 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 19 |
| Sertraline Hcl | Sertraline Hcl | 50 | 16 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 46 | 17 |
| Clotrimazole | Clotrimazole | 45 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | 16 |
| Sucralfate | Sucralfate | 45 | 11 |
| Febuxostat | Febuxostat | 44 | 15 |
| Nexletol | Bempedoic Acid | 44 | 18 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 43 | 20 |
| Glipizide | Glipizide | 42 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 16 |
| Glyxambi | Empagliflozin/Linagliptin | 39 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 17 |
| Irbesartan | Irbesartan | 38 | 13 |
| Clarithromycin | Clarithromycin | 37 | 35 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 18 |
| Furosemide | Furosemide | 37 | 27 |
| Propylthiouracil | Propylthiouracil | 37 | suppressed |
| Creon | Lipase/Protease/Amylase | 36 | 15 |
| Lubiprostone | Lubiprostone | 36 | 12 |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 14 |
| Valacyclovir | Valacyclovir Hcl | 36 | 28 |
| Chlorthalidone | Chlorthalidone | 35 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 19 |
| Calcitriol | Calcitriol | 34 | suppressed |
| Methimazole | Methimazole | 34 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 34 | suppressed |
| Gemtesa | Vibegron | 32 | suppressed |
| Colchicine | Colchicine | 31 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 30 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 28 | 14 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 28 | 16 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 28 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 26 | suppressed |
| Valsartan | Valsartan | 25 | 13 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Niacin Er | Niacin | 24 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 22 | suppressed |
| Proctozone-Hc | Hydrocortisone | 22 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 19 | 11 |
| Clonazepam | Clonazepam | 19 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 18 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 15 |
| Kerendia | Finerenone | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 14 |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Entecavir | Entecavir | 16 | suppressed |
| Nateglinide | Nateglinide | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | 15 |
| Tobramycin | Tobramycin | 16 | 16 |
| Belsomra | Suvorexant | 15 | suppressed |
| Denta 5000 Plus | Fluoride (Sodium) | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | 12 |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Ursodiol | Ursodiol | 14 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 13 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,606.66 · 196 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, Arikayce, Auvelity, BREZTRI, Brinsupri, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, EDARBI, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, JASCAYD, KISUNLA, MOUNJARO, NEXLETOL, NUCALA, OTEZLA, Ozempic, PERCEPT PC BRAINSENSE, PREVNAR 20, PYRUKYND, QULIPTA, RALDESY, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, TEPEZZA, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VYNDAMAX, ZENPEP, ZEPBOUND, ZORYVE | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error